John L McGuire
Johnson & Johnson, New Brunswick, New Jersey, United States | Johnson & Johnson, New Brunswick, New Jersey, United States, 08933 | From The R. W. Johnson Pharmaceutical ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
John L McGuire:Expert Impact
Concepts for whichJohn L McGuirehas direct influence:Gnrh antagonist,Antifertility activity,Oral administration,Arachidonic acid,Uterine contractions,Uterine contractility,Preterm labor,Oxytocin antagonist.
John L McGuire:KOL impact
Concepts related to the work of other authors for whichfor which John L McGuire has influence:Oral contraceptives,Ethinyl estradiol,Preterm labor,Uterine contractions,Contraceptive patch,Ovarian stimulation,Mast cells.
KOL Resume for John L McGuire
Johnson & Johnson, New Brunswick, New Jersey, United States
Johnson & Johnson, New Brunswick, New Jersey, United States, 08933
From The R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey
Ortho Pharmaceutical Corporation Research Laboratories Raritan, New Jersey 08869
R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08876.
Ortho Research Laboratories, Ortho Pharmaceutical Corporation, Raritan, New Jersey 08869, U.S.A.
Institute for Biomedical Research, University of Texas Austin, TX, USA
The Reproductive Endocrine Unit and the Vincent Research Laboratories, Massachusetts General Hospital, Boston, MA, USA
Research Laboratories, Ortho Pharmaceutical Corporation, Raritan, New Jersey
Research Laboratories, Ortho Pharmaceutical Corporation Raritan, New Jersey, USA.
Research Laboratories Ortho Pharmaceutical Corporation Raritan, New Jersey 08869 USA
Ortho Pharmaceutical Corporation Research Labs Route 202, Raritan, N.J. 08869, USA
Research Laboratories, Ortho Pharmaceutical Corporation, Raritan, N.J. 08869.
Research Laboratories, Ortho Pharmaceutical Corporation, 08869, Raritan, NJ, USA
Research Laboratories Ortho Pharmaceutical Corporation Raritan, New Jersey
M. S. Hershey Medical Center The Pennsylvania State University Hershey, Pennsylvania 17033 USA
Drug Disposition Section, Ortho Pharmaceutical Corporation, Raritan, NJ 08869
Ortho Pharmaceutical Corporation, Raritan, NJ 08869
Research Lboratories Ortho Pharmaceutical Corporation Raritan, New Jersey 08869 USA
|pgf2 alpha orf||#1|
|orf pgf2 alpha||#1|
|norgestimate progestogen receptor||#1|
|antifertility agents orf||#1|
|norgestimate 17deacetylated metabolite||#1|
|incubation mixtures norgestimate||#1|
|zoapatanol synthetic analog||#1|
|orf synthetic analog||#1|
|vitro studies norgestimate||#1|
|gestation fetal circulation||#1|
|dht 3keto desogestrel||#1|
|norgestimate minimal androgenicity||#1|
|greater ratio selectivity||#1|
|pharmacological tests orf||#1|
|selectivity 3keto norgestimate||#1|
|contragestational activity orf||#1|
|uterotonic activity orf||#1|
|gestodene 3keto desogestrel||#1|
|norgestimate incubation mixtures||#1|
|female diterpenes dogs||#1|
|norgestimate unique progestogen||#1|
|uterine progestogen receptors||#1|
Prominent publications by John L McGuire
Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins
[ PUBLICATION ]
The progestational and androgenic in vitro receptor binding affinity and the in vivo activity of norgestimate was compared with that of its metabolites and other progestins. The relative binding affinities (RBAs) of norgestimate and its 17-deacetylated metabolite for rabbit uterine progestin receptors were similar to that of progesterone (P); those of 3-keto norgestimate and levonorgestrel were about five times that of P; those of gestodene and 3-keto desogestrel were about nine times ...
|Known for Androgen Receptors | Norgestimate Progestins | Receptor Binding | Gestodene Levonorgestrel | 3keto Desogestrel|
Characterizing pituitary response to a gonadotropin-releasing hormone (GnRH) antagonist in monkeys: tonic follicle-stimulating hormone/luteinizing hormone secretion versus acute GnRH challenge tests b
[ PUBLICATION ]
Pituitary sensitivity to a gonadotropin-releasing hormone (GnRH) challenge test before, during, and after GnRH antagonist administration was compared in four ovariectomized female monkeys receiving GnRH antagonist intramuscularly (IM) at increasing doses of 0.3, 1.0, and 3.0 mg/kg/day over 9 days. Three days before and 3 days after treatment, monkeys received vehicle alone. On experiment days 4, 7, 10, 13, and 16, 100 micrograms of GnRH was administered intravenously (IV) and blood drawn ...
|Known for Gnrh Antagonist | Releasing Hormone | Fsh Lh | Pituitary Suppression | Follicle Stimulating|
The potencies and activities of six progestational agents, norethindrone, levonorgestrel, desogestrel, medroxyprogesterone acetate (MPA), progesterone (P) and norgestimate have been evaluated using standard laboratory bioassays. The endocrine activities measured are those most closely related to the clinically important actions of contraceptives. Relative potencies varied with parameter measured, route of administration and species showing clearly that each progestogen is a distinct ...
|Known for Norethindrone Levonorgestrel | Ovulation Inhibition | Oral Administration | Target Organs | Medroxyprogesterone Acetate|
Effects of suprofen and other prostaglandin synthstase inhibitors in a new animal model for myometrial hyperactivity
[ PUBLICATION ]
An in situ model for studying factors related to dysmenorrhea and for evaluating drugs for their inhibitory effects on uterine contractility induced by arachidonic acid and prostaglandins has been developed. Intravenous administration of arachidonic acid and PGF2 alpha to guinea pigs during the late stage of the estrous cycle, induced dose related uterine contractions and an elevation in uterine basal pressure similar to that seen in patients with dysmenorrhea. Pretreatment with ...
|Known for Arachidonic Acid | Uterine Contractions | Pgf2 Alpha | Animal Doseresponse Relationship | Effects Suprofen|
Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin
[ PUBLICATION ]
The relative binding affinity of norgestimate for human sex hormone-binding globulin was compared with that of its metabolites and other progestins by measuring their abilities to displace [3H]testosterone from this carrier protein in vitro. Norgestimate and its 17-deacetylated and 3-keto metabolites did not significantly displace [3H]testosterone from sex hormone-binding globulin at concentrations up to 10,000 nM, whereas gestodene, levonorgestrel, and 3-keto desogestrel displaced ...
|Known for Binding Globulin | Sex Hormone | Levonorgestrel Norgestrel | Norgestimate Metabolites | Norpregnenes Progesterone|
Studies with an in situ preparation of guinea pig uterus suggest the possible involvement of the lipoxygenase pathway of arachidonic acid (AA) metabolism in myometrial contractions. Female guinea pigs were sensitized to ovalbumin (OA) on day one of their estrous cycle. On day 14, these pigs were anesthetized and the uterus was cannulated for measuring contractions. OA challenge, with histamine antagonism (methapyrilene) resulted in uterine contractions which significantly raised ...
|Known for Lipoxygenase Products | Antigen Challenge | Uterine Contractions | Guinea Pigs | Estrous Cycle|
Smooth muscle contraction as a model to study the mediator role of endogenous lipoxygenase products of arachidonic acid
[ PUBLICATION ]
In the lung, the contraction of smooth muscle, or bronchospasm, is generally caused by an immunologic insult resulting in mast cell degranulation and the release of histamine, slow reacting substances, and other mediators of inflammation (1). Although the immediate response is bronchospasm, continued activation of this sequence of events results in a chronic inflammatory disease. In the uterus, numerous conditions can result in smooth muscle contraction. One major pathophysiological ...
|Known for Arachidonic Acid | Smooth Muscle | Uterine Contraction | Guinea Pigs | Lipoxygenase Products|
Terconazole is a new triazole ketal derivative with broad-spectrum in vitro and in vivo antifungal activities. This study further characterizes the effects of terconazole in vitro on yeast cell growth, viability, and morphology. Terconazole inhibited the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 10(-8) to 10(-5) M when the yeast was grown on media favoring the cell form. The inhibitory potency of terconazole on ...
|Known for Effects Terconazole | Electron Microscopy | Antifungal Agents | Candida Albicans | Broad Spectrum|
Experimental evidence for failure to implant as a mechanism of infertility associated with endometriosis
[ PUBLICATION ]
The effect of endometriosis on pregnancy, from ovulation through day 14 of pregnancy, was studied in an animal model previously developed and validated with the use of the rabbit. Endometrial tissue was implanted surgically in rabbits and allowed to grow for 11 weeks without hormonal supplementation. The animals were artificially inseminated with semen from bucks with established fertility and human chorionic gonadotropin was administered to induce ovulation. The animals were put to ...
|Known for Infertility Endometriosis | Endometrial Tissue | Animal Model | Embryo Implantation | Ascitic Fluid|
Norgestimate is a novel progestin with highly selective progestational activity and minimal androgenicity. In rabbits, norgestimate binds to uterine progestin receptors, stimulates the endometrium, and inhibits ovulation. Norgestimate acts directly on target organs, stimulating rabbit endometrium when injected into the uterine cavity and inhibiting luteinizing hormone-releasing hormone-stimulated luteinizing hormone release in dispersed rat pituitary cells in culture. Norgestimate has no ...
|Known for Androgenic Activity | Norgestimate Progestin | Androgen Receptors | Rabbits Rats | Estrogens Female|
[ PUBLICATION ]
Biotransformation, pharmacologic, and pharmacokinetic studies of norgestimate and its metabolites indicate that 17-deacetyl norgestimate, along with the parent drug, contributes to the biologic response. The postulated metabolic pathway, which is based on the identification of urinary products had indicated that three metabolites of norgestimate, 17-deacetyl norgestimate, 3-keto norgestimate, and levonorgestrel, might participate in the response. The pharmacologic evaluation of these ...
|Known for Metabolites Norgestimate | Parent Drug | 17 Deacetyl | Serum Women | Contraceptives Oral|
Evaluation of 1-deamino-[D-Tyr(Oethyl)2, Thr4, Orn8] vasotocin, an oxytocin antagonist in animal models of uterine contractility and preterm labor: A new tocolytic agent
[ PUBLICATION ]
We attempted to characterize the ability of a new oxytocin derivative, 1-deamino[D-Tyr(Oethyl)2,Thr4,Orn8] vasotocin (ORF 22164), to antagonize the action of oxytocin in several in vitro and in vivo animal models of uterine hyperactivity. In these studies, the derivative was found to be a specific competitive inhibitor of oxytocin-induced contractions of pregnant guinea pig uterus in vitro. In addition, its intravenous administration induced a dose-dependent inhibition of ...
|Known for Preterm Labor | Uterine Contractility | Oxytocin Antagonist | Animal Models | New Tocolytic Agent|